Elev what's the news on this

Here is some news about Eleva:

1. Elevation Oncology's Stock Performance: Eleva has seen a significant increase in its stock price, with a 411% rise. This impressive gain has positioned it among the top performers in the Russell 2000 index. The company's shift towards more comprehensive genetic testing, particularly in exome/genome testing, has been a key driver in its growth. This transition has not only expanded the company's margins but has also attracted positive ratings and price targets from analysts, indicating strong investor confidence.
2. Strategic Plans for EO-3021: Eleva has announced plans to evaluate EO-3021 in combination with ramucirumab and dostarlimab for the treatment of advanced gastric or gastroesophageal junction cancer. The company expects to initiate dosing in the combination portion of the Phase 1 trial by the end of 2024. These combination cohorts aim to address unmet needs across second- and first-line settings, broadening the market opportunity for EO-3021.

In summary, Eleva is focusing on expanding its market opportunity through strategic plans for EO-3021 and has experienced significant stock price appreciation due to its shift towards more comprehensive genetic testing.